Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232361 · ClinicalTrials.gov registry record
IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Completed
- Registry status
- 127
- Enrollment target
NCT01232361 is a clinical trial that has completed, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 127 participants.
The verdict
NCT01232361 has completed, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- COMPLETED
- Registry status
- 127 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out how stimulant medications (methylphenidate or amphetamine/ dextroamphetamine) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)are processed in HIV-1 infected and HIV-uninfected children and adolescents.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2010-10-08 |
| Est. Completion | 2016-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232361
The ClinicalTrials.gov registry entry for NCT01232361 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01232361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232361 about?
NCT01232361 is a clinical study titled "IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents". The main purpose of this study is to find out how stimulant medications (methylphenidate or amphetamine/ dextroamphetamine) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)are processed in HIV-1 infected and HIV-uninfected children and adolescents.
What is the current status of trial NCT01232361?
This trial is currently completed. The enrollment target is 127 participants. The study started on 2010-10-08. Estimated completion is 2016-07.
Who is sponsoring clinical trial NCT01232361?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.